Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Using MRD and PET/CT to assess responses post-ASCT in myeloma

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the results of a study investigating response assessment following autologous stem cell transplant (ASCT) in multiple myeloma. Complete response (CR) is defined using measurable residual disease (MRD) negativity measured by next-generation sequencing, and PET/CT imaging. The study examined the prognostic value of these measures at day 100 post-ASCT in 103 multiple myeloma patients. Analysis showed that MRD status and PET/CT findings were strongly correlated, with 93.9% of patients with a positive PET/CT also judged MRD positive. PET/CT was found to be a significant predictor of worse relapse-free survival and overall survival (OS), but MRD was not predictive of either. Further investigation into this combination post-ASCT is needed to optimize the approach. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Dr Rafael Fonseca, MD, has done consultancy work with Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK and AbbVie; and has participated in scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences and OncoTracker.